Abstract: The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Abstract: A heterocyclic compound represented by the general formula (1) or a salt thereof: wherein m, l, and n respectively represent an integer of 1 or 2; X represents βOβ or βCH2β; R1 represents hydrogen, a lower alkyl group, a hydroxy-lower alkyl group, a protecting group, or a tri-lower alkylsilyloxy-lower alkyl group; R2 and R3, which are the same or different, each independently represent hydrogen or a lower alkyl group; or R2 and R3 are bonded to form a cyclo-C3-C8 alkyl group; and R4 represents an aromatic group or a heterocyclic group, wherein the aromatic or heterocyclic group may have one or more arbitrary substituent(s).
Type:
Grant
Filed:
March 16, 2020
Date of Patent:
March 15, 2022
Assignee:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Nobuaki Ito, Hirofumi Sasaki, Kuninori Tai, Tomoichi Shinohara
Abstract: Ingestible event markers having high reliability are provided. Aspects of the ingestible event markers include a support, a control circuit, a first electrochemical material, a second electrochemical material and a membrane. In addition, the ingestible event markers may include one or more components that impart high reliability to the ingestible event marker. Further, the ingestible event markers may include an active agent. In some aspects, the active agent, such as a pharmaceutically active agent or a diagnostic agent may be associated with the membrane.
Type:
Application
Filed:
September 10, 2021
Publication date:
March 3, 2022
Applicant:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Hooman HAFEZI, Kit Yee AU-YEUNG, Robert DUCK, Maria HOLEN, Timothy ROBERTSON, Benedict COSTELLO
Abstract: An apparatus includes a food product, at least one ingestible device associated with the food product to communicate information and at least one coating material surrounding the at least one ingestible device is disclosed. The ingestible device is associated with an ingestible medication to be ingested in conjunction with the food product. The coating is configured to release the at least one ingestible device upon the occurrence of an event.
Type:
Application
Filed:
November 10, 2021
Publication date:
March 3, 2022
Applicant:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Lawrence Arne, Mark Zdeblick, Aditya Dua, George Savage, Robert Leichner, Jafar Shenasa, Patricia Johnson, Raymond Schmidt, Zahedeh Hatamkhany, Veeraperumanallu Muralidharan
Abstract: A test device having a micro flow channel including a reaction part where a reactant that is reactive to a tested chemical dispersed in a tested fluid is fixed, and at least one actuator for actuating the tested fluid to move in at least one of two opposite sides of the micro flow channel so as to homogenize a density distribution of the tested chemical in the tested fluid. The tested fluid is sent in the micro flow channel a plurality of times.
Abstract: A system for tracking a product from origin to destination is disclosed. The system includes a probe that comprises two plates, a power source and a processor. The power source is controlled by the processor to produce an oscillating output at the plates. Using the oscillating voltage, the probe interrogates a device through capacitive coupling. The device includes a control unit, a memory unit, and first and second materials physically associated with the device for communication using capacitive coupling. Information associated with the device is transferred from the device to the probe through capacitive coupling between the first and second materials and the first and second plates, respectively.
Abstract: A signal processing circuit processes a signal based on a quantity of light detected by an infrared detector. The signal processing circuit includes an IV conversion circuit, a filter circuit, and a differential converter circuit. The IV conversion circuit converts a signal of a current value provided from the infrared detector to a signal of a voltage value. The filter circuit allows passage of a signal containing a predetermined frequency component among signals converted by the IV conversion circuit. The differential converter circuit generates a reverse-phase signal of a passed signal that has passed through the filter circuit and provides a differential signal including the passed signal and the reverse-phase signal.
Abstract: The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can also measure the conditions of the environment surrounding the system.
Type:
Grant
Filed:
November 20, 2019
Date of Patent:
January 25, 2022
Assignee:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Jeremy Frank, Peter Bjeletich, Hooman Hafezi, Robert Azevedo, Robert Duck, Iliya Pesic, Benedict Costello, Eric Snyder
Abstract: This invention relates to methods and compositions for administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine. In particular, the invention relates to methods for treating cancer, inhibiting degradation of a CDA substrate drug, and reducing DNA methylation in a subject in need thereof comprising administering an effective amount of a CDA substrate drug and an effective amount of cedazuridine.
Type:
Grant
Filed:
September 18, 2019
Date of Patent:
January 18, 2022
Assignee:
Otsuka Pharmaceutical Co., Ltd.
Inventors:
Harold Keer, Mohammad Azab, Aram Oganesian
Abstract: A target authentication device includes an electrode to detect an electrical signal associated with a user of the device. The electrical signal represents an authentication code for the device. An authentication receiver module is coupled to the electrode. The module receives the electrical signal from the electrode and determines whether the electrical signal matches a predetermined criterion to authenticate the identity of the user based on the electrical signal. An authentication module is also disclosed. The authentication module includes one electrode to couple an electrical signal associated with a user to a user of a target authentication device, the electrical signal represents an authentication code for the device. An authentication transmission module is coupled to the electrode. The authentication transmission module transmits the electrical signal from the electrode. A method of authenticating the identity of a user of a target authentication device also is disclosed.
Type:
Application
Filed:
September 24, 2021
Publication date:
January 13, 2022
Applicant:
OTSUKA PHARMACEUTICAL CO. LTD.
Inventors:
Timothy Robertson, George Savage, Benedict Costello, David O'reilly
Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water.
Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (I) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
Type:
Application
Filed:
March 10, 2021
Publication date:
January 6, 2022
Applicant:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
Abstract: The present invention relates to a method of mono-alkylating a piperidine nitrogen in a piperidine derivative with a deuterated lower-alkyl, which comprises protecting the piperidine nitrogen with an aralkyl protective group, lower-alkylating the piperidine nitrogen with a deuterated-lower-alkylating agent under neutral or basic condition, and then deprotecting the aralkyl protective group.
Abstract: The ingestible event marker data framework provides a uniform, comprehensive framework to enable various functions and utilities related to ingestible event marker data (IEM data). The functions and utilities include data and/or information having an aspect of data derived from, collected by, aggregated by, or otherwise associated with, an ingestion event.
Type:
Grant
Filed:
April 26, 2017
Date of Patent:
January 4, 2022
Assignee:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
David O'Reilly, Erika Karplus, Andrew Thompson, George Savage, Mark Zdeblick, Timothy Robertson, Lawrence Arne, Yashar Behzadi, Gregory Moon, Patrick Beaulieu
Abstract: The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: wherein the symbols are as defined in the specification, which is useful for treating, preventing and/or diagnosing seizure and the like in disease involving epileptic seizure or convulsive seizure (including multiple drug resistant seizure, refractory seizure, acute symptomatic seizure, febrile seizure and status epilepticus), as well as a medical use therefor.
Abstract: An apparatus includes a food product, at least one ingestible device associated with the food product to communicate information and at least one coating material surrounding the at least one ingestible device is disclosed. The ingestible device is associated with an ingestible medication to be ingested in conjunction with the food product. The coating is configured to release the at least one ingestible device upon the occurrence of an event.
Type:
Grant
Filed:
July 17, 2019
Date of Patent:
December 14, 2021
Assignee:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Lawrence Arne, Mark Zdeblick, Aditya Dua, George Savage, Robert Leichner, Jafar Shenasa, Patricia Johnson, Raymond Schmidt, Zahedeh Hatamkhany, Veeraperumanallu Muralidharan
Abstract: An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains ?-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering ?-tocopherol and equol, wherein 0.1 to 1000 mg per day of ?-tocopherol and 0.1 to 50 mg per day of equol are administered.
Abstract: An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains ?-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering ?-tocopherol and equol, wherein 0.1 to 1000 mg per day of ?-tocopherol and 0.1 to 50 mg per day of equol are administered.
Abstract: The present invention discloses multiple approaches to preventing the capsule walls and other material from interfering with the performance of an electronic device once the device is activated by surrounding fluid. In accordance with the teachings of the present invention, a miniature ingestible device (MID) may be created using excipients and films. The MID, in accordance with various aspects of the present invention, will have a coating or laminating surrounding an electronic device and separating and isolating the device from the pharmaceutical product or drug within the capsule once the capsule is ingested as well as from the capsule itself as the capsule walls begin to collapse during the disintegration process.
Type:
Grant
Filed:
February 1, 2019
Date of Patent:
November 16, 2021
Assignee:
OTSUKA PHARMACEUTICAL CO., LTD.
Inventors:
Timothy Robertson, Hooman Hafezi, Raymond Schmidt
Abstract: Provided herein are compositions for the ingestible administration of lisinopril. In some embodiments the compositions comprise lisinopril and silicon. In some embodiments, the compositions comprise lisinopril, silicon, magnesium metal, and copper (I) chloride. Also provided herein are apparatuses comprising the compositions provided herein. Also provided herein are methods for using the compositions and apparatuses provided herein.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
November 9, 2021
Assignee:
OTSUKA PHARMACEUTICAL CO. LTD
Inventors:
Kurt Scheinpflug, Nikhil Pargaonkar, Chris Dong, Ai Ling Ching, Dawn Adkin